Donafenib 28 is a protein kinase and angiogenesis inhibitor undergoing a number of clinical trials for oncology indications, including the treatment of metastatic colorectal cancer, 45, 46 metastatic gastric cancer, 47 advanced esophageal cancer, 48 advanced hepatocellular cancer, 49, 50 and metastatic nasopharyngeal cancer <a href=http://lasix.autos/>lasix high dose</a> |
|